Lisata Historical Balance Sheet

LSTA Stock

USD 2.88 0.04 1.41%

Trend analysis of Lisata Therapeutics balance sheet accounts such as Total Current Liabilities of 8.5 M provides information on Lisata Therapeutics' total assets, liabilities, and equity, which is the actual value of Lisata Therapeutics to its prevalent stockholders. By breaking down trends over time using Lisata Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Lisata Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lisata Therapeutics is a good buy for the upcoming year.

Lisata Therapeutics Inventory

4.54 Million

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lisata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.

About Lisata Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Lisata Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Lisata Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Lisata Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Lisata currently owns. An asset can also be divided into two categories, current and non-current.

Lisata Therapeutics Balance Sheet Chart

At present, Lisata Therapeutics' Total Current Liabilities is projected to decrease significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 50.6 M, whereas Total Assets are forecasted to decline to about 43.4 M.

Total Assets Other Current Liab Total Current Liabilities Good Will

Total Assets

Total assets refers to the total amount of Lisata Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lisata Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Lisata Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Lisata Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Good Will

An intangible asset that arises when a company acquires another business for more than the fair market value of its net identifiable assets, representing the value of the brand, customer base, and other intangible factors.

Most accounts from Lisata Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Lisata Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lisata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.At present, Lisata Therapeutics' Total Current Liabilities is projected to decrease significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 50.6 M, whereas Total Assets are forecasted to decline to about 43.4 M.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	714K	485K	305K	289.8K
Total Assets	97.0M	73.0M	54.7M	43.4M

Short Long Term Debt Total Total Assets

Lisata Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Non Current Assets Total	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Non Currrent Assets Other	Intangible Assets	Cash	Cash And Short Term Investments	Good Will	Short Term Investments	Current Deferred Revenue
Total Assets		0.35	0.68	0.68	0.7	0.46	-0.02	0.12	0.5	0.81	0.12	-0.11	0.72	0.37	-0.02	0.75	0.38	0.27	0.19	0.65	0.63	0.19	0.11	0.63	0.01	0.1
Short Long Term Debt Total	0.35		0.09	0.52	-0.13	0.83	0.45	0.22	0.81	0.56	0.79	-0.38	0.7	0.71	-0.23	0.68	-0.32	0.7	0.17	0.01	0.65	-0.02	-0.39	0.55	-0.22	0.66
Other Current Liab	0.68	0.09		0.86	0.21	0.31	0.29	0.32	0.07	0.73	-0.11	-0.2	0.52	0.14	-0.27	0.68	-0.01	0.43	0.28	0.97	0.19	-0.28	-0.32	0.13	-0.28	-0.13
Total Current Liabilities	0.68	0.52	0.86		0.04	0.71	0.43	0.3	0.5	0.84	0.33	-0.31	0.76	0.46	-0.28	0.89	-0.19	0.76	0.3	0.79	0.4	-0.23	-0.48	0.34	-0.33	0.26
Total Stockholder Equity	0.7	-0.13	0.21	0.04		-0.14	-0.55	-0.3	0.12	0.2	-0.27	0.36	0.08	0.0	0.43	0.07	0.87	-0.32	-0.08	0.22	0.23	0.55	0.74	0.39	0.47	-0.11
Property Plant And Equipment Net	0.46	0.83	0.31	0.71	-0.14		0.33	0.34	0.83	0.71	0.72	-0.48	0.81	0.59	-0.35	0.82	-0.37	0.84	0.3	0.23	0.6	0.03	-0.5	0.48	-0.34	0.52
Net Debt	-0.02	0.45	0.29	0.43	-0.55	0.33		0.48	0.09	0.41	0.35	-0.41	0.41	0.25	-0.54	0.44	-0.69	0.58	0.47	0.33	0.27	-0.9	-0.75	0.08	-0.38	0.11
Retained Earnings	0.12	0.22	0.32	0.3	-0.3	0.34	0.48		-0.07	0.5	0.09	-0.66	0.4	-0.14	-0.99	0.39	-0.62	0.34	0.74	0.39	0.37	-0.44	-0.69	0.02	-0.66	-0.48
Accounts Payable	0.5	0.81	0.07	0.5	0.12	0.83	0.09	-0.07		0.55	0.81	-0.06	0.74	0.82	0.08	0.69	-0.03	0.55	-0.04	-0.02	0.67	0.3	-0.12	0.69	-0.09	0.69
Non Current Assets Total	0.81	0.56	0.73	0.84	0.2	0.71	0.41	0.5	0.55		0.36	-0.41	0.92	0.42	-0.45	0.95	-0.22	0.58	0.44	0.73	0.78	-0.19	-0.48	0.66	-0.49	0.07
Net Receivables	0.12	0.79	-0.11	0.33	-0.27	0.72	0.35	0.09	0.81	0.36		-0.1	0.6	0.74	-0.1	0.53	-0.32	0.49	-0.07	-0.16	0.5	0.0	-0.34	0.48	-0.21	0.6
Common Stock Shares Outstanding	-0.11	-0.38	-0.2	-0.31	0.36	-0.48	-0.41	-0.66	-0.06	-0.41	-0.1		-0.43	0.17	0.72	-0.43	0.55	-0.45	-0.4	-0.19	-0.33	0.3	0.58	-0.02	0.4	-0.06
Non Current Liabilities Total	0.72	0.7	0.52	0.76	0.08	0.81	0.41	0.4	0.74	0.92	0.6	-0.43		0.6	-0.37	0.97	-0.25	0.57	0.23	0.48	0.85	-0.12	-0.46	0.73	-0.42	0.33
Other Current Assets	0.37	0.71	0.14	0.46	0.0	0.59	0.25	-0.14	0.82	0.42	0.74	0.17	0.6		0.12	0.58	-0.04	0.44	-0.18	0.05	0.47	0.06	-0.15	0.47	-0.02	0.66
Other Stockholder Equity	-0.02	-0.23	-0.27	-0.28	0.43	-0.35	-0.54	-0.99	0.08	-0.45	-0.1	0.72	-0.37	0.12		-0.37	0.71	-0.38	-0.71	-0.34	-0.31	0.5	0.76	0.06	0.68	0.41
Total Liab	0.75	0.68	0.68	0.89	0.07	0.82	0.44	0.39	0.69	0.95	0.53	-0.43	0.97	0.58	-0.37		-0.24	0.68	0.28	0.62	0.73	-0.17	-0.49	0.62	-0.41	0.32
Total Current Assets	0.38	-0.32	-0.01	-0.19	0.87	-0.37	-0.69	-0.62	-0.03	-0.22	-0.32	0.55	-0.25	-0.04	0.71	-0.24		-0.48	-0.4	-0.05	-0.17	0.62	0.95	0.06	0.77	0.04
Short Term Debt	0.27	0.7	0.43	0.76	-0.32	0.84	0.58	0.34	0.55	0.58	0.49	-0.45	0.57	0.44	-0.38	0.68	-0.48		0.51	0.36	0.28	-0.32	-0.62	0.15	-0.26	0.44
Common Stock	0.19	0.17	0.28	0.3	-0.08	0.3	0.47	0.74	-0.04	0.44	-0.07	-0.4	0.23	-0.18	-0.71	0.28	-0.4	0.51		0.39	0.26	-0.46	-0.48	0.02	-0.34	-0.42
Non Currrent Assets Other	0.65	0.01	0.97	0.79	0.22	0.23	0.33	0.39	-0.02	0.73	-0.16	-0.19	0.48	0.05	-0.34	0.62	-0.05	0.36	0.39		0.2	-0.37	-0.35	0.12	-0.33	-0.29
Intangible Assets	0.63	0.65	0.19	0.4	0.23	0.6	0.27	0.37	0.67	0.78	0.5	-0.33	0.85	0.47	-0.31	0.73	-0.17	0.28	0.26	0.2		0.02	-0.28	0.91	-0.42	0.17
Cash	0.19	-0.02	-0.28	-0.23	0.55	0.03	-0.9	-0.44	0.3	-0.19	0.0	0.3	-0.12	0.06	0.5	-0.17	0.62	-0.32	-0.46	-0.37	0.02		0.66	0.19	0.31	0.19
Cash And Short Term Investments	0.11	-0.39	-0.32	-0.48	0.74	-0.5	-0.75	-0.69	-0.12	-0.48	-0.34	0.58	-0.46	-0.15	0.76	-0.49	0.95	-0.62	-0.48	-0.35	-0.28	0.66		-0.04	0.82	0.05
Good Will	0.63	0.55	0.13	0.34	0.39	0.48	0.08	0.02	0.69	0.66	0.48	-0.02	0.73	0.47	0.06	0.62	0.06	0.15	0.02	0.12	0.91	0.19	-0.04		-0.26	0.27
Short Term Investments	0.01	-0.22	-0.28	-0.33	0.47	-0.34	-0.38	-0.66	-0.09	-0.49	-0.21	0.4	-0.42	-0.02	0.68	-0.41	0.77	-0.26	-0.34	-0.33	-0.42	0.31	0.82	-0.26		0.31
Current Deferred Revenue	0.1	0.66	-0.13	0.26	-0.11	0.52	0.11	-0.48	0.69	0.07	0.6	-0.06	0.33	0.66	0.41	0.32	0.04	0.44	-0.42	-0.29	0.17	0.19	0.05	0.27	0.31

Click cells to compare fundamentals

Lisata Therapeutics Account Relationship Matchups

Lisata Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	27.2M	36.0M	97.0M	73.0M	54.7M	43.4M
Other Current Liab	1.6M	2.1M	2.4M	3.5M	4.0M	3.4M
Total Current Liabilities	6.0M	3.5M	4.5M	6.4M	6.6M	8.5M
Total Stockholder Equity	20.8M	32.5M	92.3M	66.6M	48.1M	50.6M
Property Plant And Equipment Net	100K	57K	62K	296K	483K	458.9K
Net Debt	(13.7M)	(15.9M)	(23.9M)	(31.7M)	(22.3M)	(21.2M)
Retained Earnings	(417.4M)	(425.6M)	(453.0M)	(507.2M)	(528.1M)	(501.7M)
Accounts Payable	1.5M	1.0M	1.9M	2.7M	2.4M	2.4M
Non Current Assets Total	1.2M	671K	826K	1.2M	770K	731.5K
Common Stock Shares Outstanding	688.3K	1.0M	3.7M	5.2M	8.1M	8.5M
Liabilities And Stockholders Equity	27.2M	36.0M	97.0M	73.0M	54.7M	43.4M
Non Current Liabilities Total	624K	254K	485K	327K	210K	199.5K
Other Current Assets	815K	758K	1.2M	2.7M	3.4M	1.7M
Other Stockholder Equity	438.2M	458.0M	545.3M	573.8M	576.3M	605.1M
Total Liab	6.6M	3.8M	5.0M	6.7M	6.8M	6.5M
Total Current Assets	26.0M	35.3M	96.2M	71.9M	53.9M	56.6M
Accumulated Other Comprehensive Income	2K	(13K)	(70K)	(29K)	(42K)	(44.1K)
Common Stock	11K	19K	60K	8K	7.2K	6.8K
Non Currrent Assets Other	1.1M	614K	764K	528K	24K	22.8K
Cash	14.0M	16.5M	24.6M	32.2M	22.6M	23.7M
Cash And Short Term Investments	25.2M	34.6M	95.0M	69.2M	50.5M	53.1M
Short Term Investments	11.1M	18.1M	70.3M	37.1M	27.9M	18.7M
Other Assets	309K	0.0	40K	1.2M	1.4M	1.5M
Net Invested Capital	20.8M	32.5M	92.3M	66.6M	48.1M	54.6M
Capital Stock	11K	19K	60K	8K	9.2K	8.7K
Net Working Capital	20.0M	31.8M	91.7M	65.5M	47.3M	54.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Lisata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lisata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lisata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lisata Therapeutics Stock:

How To Invest In Lisata

Details

Is Lisata Stock a good investment?

Details

What is Lisata Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.

You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lisata Therapeutics. If investors know Lisata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lisata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.51)

Return On Assets

(0.29)

Return On Equity

(0.44)

The market value of Lisata Therapeutics is measured differently than its book value, which is the value of Lisata that is recorded on the company's balance sheet. Investors also form their own opinion of Lisata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lisata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lisata Therapeutics' market value can be influenced by many factors that don't directly affect Lisata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lisata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lisata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lisata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lisata Historical Balance Sheet

Lisata Therapeutics Inventory

4.54 Million

About Lisata Balance Sheet Analysis

Lisata Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Good Will

Lisata Therapeutics balance sheet Correlations

Lisata Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lisata Therapeutics balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Currrent Assets Other	+ 0.97	Other Current Liab
Total Liab	+ 0.97	Non Current Liabilities Total
Total Liab	+ 0.95	Non Current Assets Total
Cash And Short Term Investments	+ 0.95	Total Current Assets
Non Current Liabilities Total	+ 0.92	Non Current Assets Total
Good Will	+ 0.91	Intangible Assets

Other Stockholder Equity	- 0.99	Retained Earnings
Cash	- 0.9	Net Debt
Cash And Short Term Investments	- 0.75	Net Debt
Common Stock	- 0.71	Other Stockholder Equity
Cash And Short Term Investments	- 0.69	Retained Earnings
Total Current Assets	- 0.69	Net Debt